Amylin Can't Block Lilly's Rival Drug Sales: 9th Circ.
By Carolina Bolado ( October 31, 2011, 8:50 PM EDT) -- The Ninth Circuit on Monday affirmed a ruling denying Amylin Pharmaceuticals Inc.'s request to block Eli Lilly & Co. from allegedly violating a joint marketing agreement and breaching antitrust laws by selling Amylin's diabetes drug alongside rival treatments made by Boehringer Ingelheim GmbH....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.